Neos Therapeutics to Host Second Quarter 2016 Financial Results Conference Call on August 11, 2016
August 02, 2016 07:00 ET
|
Neos Therapeutics, Inc
DALLAS-FORT WORTH, Texas, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics Announces Successful Completion of Bioequivalence Bridging Study for Cotempla XR-ODT™ (Methylphenidate Extended-Release Orally Disintegrating Tablet)
July 28, 2016 16:05 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, July 28, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics CEO to Present at JMP Securities Life Sciences Conference on June 21, 2016
June 14, 2016 07:00 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 14, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics Appoints Juergen Martens as Chief Technology and Operations Officer
May 31, 2016 16:05 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 31, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics CEO to Present at 2016 UBS Healthcare Conference on May 24, 2016
May 17, 2016 07:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics Announces Closing of $60 Million Term Debt Financing and First Quarter 2016 Financial Results
May 16, 2016 06:05 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...
Neos Therapeutics Announces U.S. Launch of Adzenys XR-ODT™ (Amphetamine Extended-Release Orally Disintegrating Tablet) for the Treatment of ADHD in Patients Six Years and Older
May 16, 2016 06:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR)...
Neos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on May 16, 2016
May 05, 2016 07:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, May 05, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative...
Neos Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results
March 17, 2016 07:00 ET
|
Neos Therapeutics, Inc.
Launch of Adzenys XR-ODT in Second Quarter of 2016 Company to Host Conference Call at 8:30am ET Today DALLAS/FORT WORTH, Texas, March 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc....
Neos Therapeutics Announces Date of Fourth Quarter and 2015 Fiscal Year Financial Results
March 08, 2016 07:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, March 08, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release...